Some studies have examined the potential of CD47 as an anti-cancer therapeutic target to prevent immune evasion of tumor cells (28); however, the CD47-targeted therapies tested thus far have shown low efficacy and limited benefit. The gene discussed is CD47; the disease is neoplasm.